Core Viewpoint - Hansoh Pharmaceutical announced a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, a CDH17-targeted antibody-drug conjugate for colorectal cancer and other solid tumors [1] Group 1: Licensing Agreement Details - The agreement involves Hansoh's wholly-owned subsidiary Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. as licensors [1] - Hansoh will receive an upfront payment of $80 million and is eligible for up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Future potential sales will also generate tiered royalties for Hansoh [1] Group 2: Product and Clinical Trials - HS-20110 is currently undergoing global Phase I clinical trials in China and the United States for the treatment of colorectal cancer and other solid tumors [1] - The product represents a significant advancement in targeted cancer therapy, leveraging antibody-drug conjugate technology [1] Group 3: Roche Overview - F. Hoffmann-La Roche Ltd is a subsidiary of Roche Holding AG, which is listed on the Swiss Stock Exchange [1] - Roche was established in 1896 in Basel, Switzerland, and has evolved into a leading global biotechnology company and a leader in in vitro diagnostics [1]